Financial Performance - Operating revenue for Q1 2023 was ¥76,810,113.89, a decrease of 41.44% year-on-year from ¥131,171,039.95 in Q1 2022[14] - Net profit attributable to shareholders for Q1 2023 was ¥5,290,570.22, down 79.12% from ¥25,343,047.44 in the same period last year[14] - Basic earnings per share decreased by 84.34% to ¥0.0547 in Q1 2023, compared to ¥0.3493 in Q1 2022[14] - Total operating revenue for Q1 2023 was CNY 76,810,113.89, a decrease of 41.5% compared to CNY 131,171,039.95 in Q1 2022[44] - Net profit for Q1 2023 was CNY 5,290,570.22, a decline of 79.1% from CNY 25,343,047.44 in Q1 2022[46] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0547, compared to CNY 0.3493 in Q1 2022[46] - The total comprehensive income for Q1 2023 was CNY 10,004,504.66, compared to CNY 26,961,415.29 in Q1 2022, indicating a significant decline[50] Cash Flow - The net cash flow from operating activities increased by 181.31% to ¥10,886,241.11, compared to a negative cash flow of ¥13,389,261.33 in the previous year[14] - Cash flow from operating activities generated a net amount of CNY 10,886,241.11, recovering from a negative cash flow of CNY -13,389,261.33 in Q1 2022[51] - Total cash inflow from operating activities was CNY 113,368,350.44, an increase of 9.0% from CNY 103,067,482.34 in Q1 2022[51] - Cash outflow from operating activities decreased to CNY 102,482,109.33 from CNY 116,456,743.67, reflecting a reduction of 12.0%[51] - The net cash flow from financing activities was -$4,037,660.20, a decline from a positive net cash flow of $10,146,527.78 in the previous year[55] - The total cash and cash equivalents at the end of the period were $430,429,534.93, up from $177,941,981.52 at the end of the same quarter last year[55] Assets and Liabilities - Total assets as of March 31, 2023, amounted to ¥813,520,667.67, representing a 0.79% increase compared to the end of 2022[14] - The total liabilities to assets ratio (consolidated) was 25.38%, slightly down from 25.52% at the end of 2022[14] - The company's total liabilities stood at ¥206,474,159.01, which is a marginal increase from ¥205,972,761.11, showing a growth of about 0.2%[38] - The company's equity attributable to shareholders increased to ¥607,046,508.66 from ¥601,137,835.64, marking an increase of approximately 1%[38] - The company's cash and cash equivalents decreased to ¥495,099,137.70 from ¥582,090,924.03, representing a decline of about 15%[36] Shareholder Information - The number of ordinary shareholders as of the report date was 9,439, with a total share capital of 96,730,934 shares[23] - The largest shareholder, Changhong Meiling Co., Ltd., holds 45,900,000 shares, representing 47.45% of total shares[24] - The second largest shareholder, Zhongke Xianxing (Beijing) Asset Management Co., Ltd., holds 19,500,000 shares, accounting for 20.16%[24] - The total shares held by the top ten shareholders amount to 71,492,439, which is 73.91% of the total shares[25] Legal and Compliance - A lawsuit involving Zhejiang Terwis Pharmaceutical Co., Ltd. claims an amount of 5,603,675 yuan, which represents 0.92% of the company's net assets[30] - The company has recognized a provision for potential repair costs related to the ongoing lawsuit, indicating a proactive approach to financial risk management[30] - The company has not engaged in any external borrowing or significant related party transactions during the reporting period[28] - There are no major external guarantees or asset pledges reported for the current period[28] - The company has fulfilled all disclosed commitments in a timely manner, ensuring compliance with regulatory requirements[28] Research and Development - Research and development expenses increased by ¥1,612,500, reflecting a focus on enhancing growth momentum despite reduced revenue[15] - The company plans to accelerate the development of strategic products such as biological safety cabinets and centrifuges, while expanding market channels[15] - Research and development expenses for Q1 2023 were CNY 8,189,437.30, an increase of 24.6% from CNY 6,576,964.88 in Q1 2022[45] Inventory and Receivables - The company's inventory increased to ¥49,991,209.24 from ¥48,074,736.13, reflecting a growth of about 4%[36] - The company's accounts receivable decreased to ¥4,202,695.38 from ¥5,852,225.38, indicating a decline of approximately 28%[36]
中科美菱(835892) - 2023 Q1 - 季度财报